

# An Open Letter to People Impacted by Cancer from BeiGene Employees

At BeiGene, we strive every day to create innovative medicines that are more accessible to people who need them. Our core value of putting patients first drives everything we do.

In 2010, our founders John V. Oyler and Xiaodong Wang envisioned a new model to develop and deliver cancer medicines more broadly to people, regardless of where they live in the world. Their view was, and remains, that pioneering groundbreaking research and therapies is not enough. That's why we are committed to ensuring more patients, regardless of geography, race, or socioeconomic status, can access them.

As BeiGene colleagues, we are proud of what we have accomplished in the past 12 years. We have grown from an idea in 2010 to our first FDA approval in 2019.

Today, we are helping people impacted by mantle cell lymphoma, marginal zone lymphoma, Waldenström's macroglobulinemia, and now chronic lymphocytic leukemia.

## ***But we did not do this alone. We are here because of you.***

We are here because we believe in open and transparent partnerships with patient and healthcare professional communities in the U.S., Europe, Australia, Brazil, and other regions and countries where we work. You are the people who trusted us, and who teach us, support us, and inspire us, every day.

So today, BeiGene employees – more than 9,000 of us working in 29 countries and regions around the world – want to take this moment to say a heartfelt “thank you.”

- Thank you to the tens of thousands of people and their families who have trusted BeiGene, shared thoughtful insights, and participated in our clinical trials.
- Thank you to the many research centers and healthcare professionals who continue to guide our clinical trials and have helped lead key programs.
- And thank you to the patient advocacy organizations and allied health professional groups who have built partnerships with us to support people impacted by cancer.

This is just the beginning in our fight against cancer. Together, we will continue to grow globally, advance our pipeline of therapies, and address inequities in access to cancer treatment around the world.

With each step forward, we will be guided by our commitment to making innovative treatments more accessible to more people globally. As we often say at BeiGene, cancer has no borders, and neither do we.

***Thank You,  
The Colleagues of BeiGene***